Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HST-002
Therapeutic Area: Dermatology Product Name: HST-002
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
Histogen received communications from the Office of Combination Products that HST-002 is a drug-biologic-device combination product. HST-001 1b/2a trial for androgenic alopecia in men on track for top line data results in 4Q20.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KT-474
Therapeutic Area: Dermatology Product Name: KT-474
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 31, 2020
Details:
Kymera expects to file an IND for KT-474, an orally bioavailable IRAK4 degrader, in the 1H 2021. If approved, the company will initiate a Phase 1 trial in adult healthy volunteers and hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SFA002
Therapeutic Area: Dermatology Product Name: SFA002
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enroll 15 patients into treatment with an initial formulation of SFA002 and an additional 15 subjects into treatment with a second formulation.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
